Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NKG2D CAR-NK in Liver Metastatic Colorectal Cancer
NCT05248048Phase 1Unknown
- Sponsor
- The Third Affiliated Hospital of Guangzhou Medical University
- Start
- Sep 2021
- Primary completion
- Oct 2022
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NKG2D CAR NK cells in colorectal cancer (CRC), sponsored by The Third Affiliated Hospital of Guangzhou Medical University. Primary endpoints: Dose-Limiting Toxicity at 28 days and Maximal Tolerable Dose at 28 days. Status: unknown.
02
Drugs
NKG2D CAR NK cells
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05248048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05248048.